PURPOSE: @entity5 ( @entity5 ) is rare and prone to metastasize. We conducted a prospective study to evaluate the role of @entity419 PET in the management of this @entity146 . METHODS: @entity1 with untreated primary, histologically confirmed @entity5 were enrolled. @entity419 PET (or PET/CT) was performed immediately after MRI or CT, for primary staging, monitoring response to treatment or restaging when there was suspicion of recurrence. The clinical impact of PET was determined on a scan basis. RESULTS: A total of 25 @entity1 were recruited and 43 PET scans were performed. The PET images were obtained for primary staging (25 @entity1 ), monitoring response (10 @entity1 ) and restaging when there was suspicion of recurrence (8 @entity1 ). The median follow-up time in event-free @entity1 was 109.3  months (range 97.5  -  157.7  months). A positive impact of PET was found in 8 (18.6  %) of the 43 scans, which included detection of additional regions of distal @entity1600 ( @entity1600 ) @entity3 (one primary staging scan, two restaging scans), bone @entity3 (two primary staging scans, one monitoring response scan), and exclusion of @entity75 on MRI (one primary staging scan, one restaging scan). On the other hand, one negative impact was recorded as one false-positive lesion on a restaging PET scan. One positive impact was noted for monitoring response (bone @entity3 ). The impact of three scans was indeterminate. The positive impact of down-staging in avoiding overtreatment but finding additional distal @entity1600 (except one on restaging) or bone metastases had no beneficial effect on long-term survival. CONCLUSION: The results of this preliminary study suggest that PET is useful in the management of @entity5 . PET could have more value in detecting occult metastases if future novel therapies are able to offer better control of extensive @entity5 .

XXXX PET in @entity5 : a prospective study with long-term follow-up.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18)F-FDG'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive malignancy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Small-cell cervical cancer', 'SCCC'] @entity75 :: ('MESH:D001927', 'Disease') :: ['false-positive lesions'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['LN', 'lymph node'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity419 :: (MESH:D019788,Chemical) :: ['(18)F-FDG']
